NEW YORK, NY / ACCESSWIRE / January 30, 2019 /U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The Dow Jones Industrial Average was up 0.21 percent to close at 24,579.96, led higher by 3M and Pfizer, while the S&P 500 fell 0.15 percent to settle at 2,640. The Nasdaq plunged 0.81 percent 7,028.29.
Lewis Alexander, The Chief U.S. economist at Nomura said, “Since the December meeting, Fed officials appeared to have delivered a coordinated message that the committee is ready to pause on quarterly rate hikes. The committee appears to be willing to wait until heightened uncertainty around the economic outlook dissipates before raising rates again.”
The Market Wealth Report Initiates Coverage on:
Zynerba Pharmaceuticals, Inc.
BioTime's stock jumped 55.46% Tuesday, to close the day at $1.39. The stock recorded a trading volume of 10,069,223 shares, which was above its three months average volume of 605,486 shares. In the last year, BioTime's shares have traded in a range of 0.66 - 3.11. The share price has gained 110.61% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.04 is below its 200-day moving average of $1.91. Shares of BioTime have gained roughly 46.32 percent in the past month and are up 52.75 percent year-to-date.
Access The Market Wealth's BioTime, Inc. Research Report:
On Tuesday, shares of Zynerba Pharmaceuticals recorded a trading volume of 7,753,236 shares, which was above the three months average volume of 299,921 shares. The stock ended the day 25.26% higher at $4.81. The share price has fallen 62.94% from its 52
Access The Market Wealth's Zynerba Pharmaceuticals, Inc. Research Report:
The Market Wealth Report
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Wealth Report has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketWealthReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketWealthReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketwealthreport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Wealth Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Market Wealth Report